IONPs, functioned with n-hydroxysuccinimide, were conjugated with vascular endothelial growth factor (VEGF) antibody and ligand cluster of differentiation 80 (CD80) (IONPs@CD80 + VEGF) to treat human osteosarcoma. Here, CD80 is linked to osteosarcoma.